Clinical Trial: Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07092514) titled 'Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)' on July 21.

Brief Summary: This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).

Study Start Date: Oct. 31, 2025

Study Type: INTERVENTIONAL

Condition: Thyroid Cancer Cancer of the Thyroid

Intervention: DRUG: Lenvatinib

Lenvatinib is an oral drug which will be administered on an outpatient basis at a dose of 24 mg...